Takeda
Pharmaceutical Co. Ltd. Eyes Russia Growth With $96 Million Drug
Plant
State-of-the-art facility in Yaroslavl demonstrates Takeda's long-term commitment to the Russian market.
Plant
expected to be fully operational in 2014, supplying high quality tablet and
sterile liquid products for the local market.
Takeda
Pharmaceutical International GmbH ("Takeda") today announced the
completion of construction at its pharmaceutical manufacturing facility in
Yaroslavl, Russia. The Company has invested approximately €75 million in the
24,000m2 production plant, which is expected to be fully operational by 2014.
Takeda was
one of the first major international companies to have invested in high quality
pharmaceutical manufacturing in Russia, demonstrating its long-term commitment
to the market. Based on sales Takeda is the 7th largest pharmaceutical company
in Russia. According to IMS Health, Russian pharmaceutical sales totaled $14.7
billion* in 2011, making it the 11th largest pharmaceutical market in the
world. Market sales in Russia/CIS are expected to grow at a compound annual
rate of 11%* between 2012 and 2016. Takeda plans to outgrow the market with an
annual growth rate of 15% over the same period.
The Yaroslavl facility will enable Takeda to meet demand in Russia, initially Cardiomagnyl, Actovegin and Calcium tablets. It will lead to creation of initially around 200 positions for highly qualified managers and technical staff.
The plant,
which is approximately 280 kilometers from Moscow, was constructed on time and
on budget to local and international GMP standards and adheres to the latest
safety and environmental standards. It will have the initial capacity to
manufacture 90 million sterile ampoules and more than two billion tablets per
year. Liquid sterile production includes solution preparation, washing of ampoules,
sterilization, filling, inspection, and packaging. Solid production will
encompass all stages, from weighing, mixing and granulation through
compression, coating, and packaging.
"The
completion of this ambitious project further demonstrates Takeda's transition
into a truly global business, and strategic investment into key emerging
markets such as Russia is a major part of this strategy." said Yasuchika
Hasegawa, President & Chief Executive Officer of Takeda Pharmaceutical
Company Limited. "Russia is our largest emerging market in terms of
revenues, and is expected to contribute significantly to our growth over the
next few years. The Yaroslavl facility will enable us to provide locally
produced pharmaceutical products to patients and clinicians, as well as
bringing significant benefits to the Yaroslavl and Russian economy."
"Takeda
is one of the flagship companies in Yaroslavl's pharmaceutical cluster and is
the first major international pharmaceutical company to invest in a new world
class manufacturing facility in the region," added Sergey Yastrebov, the
Governor of Yaroslavl Region. "This project is an excellent example of the
benefits that international investment can bring to the Russian economy. Takeda
is working closely with Russian companies to build the plant, and will create
hundreds of high quality jobs for Russian people in the future."
Surplus Equipment Wanted For Purchase. Should you have any used process, packaging, pharmaceutical, or laboratory equipment, please contact SSLLC.com
http://www.ssllc.com/SellYourEquipment.aspx
Surplus Equipment Wanted For Purchase. Should you have any used process, packaging, pharmaceutical, or laboratory equipment, please contact SSLLC.com
http://www.ssllc.com/SellYourEquipment.aspx
